Simplify Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,591 shares of the biopharmaceutical company's stock after acquiring an additional 3,231 shares during the quarter. Regeneron Pharmaceuticals makes up 0.5% of Simplify Asset Management Inc.'s portfolio, making the stock its 22nd biggest position. Simplify Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $10,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. SteelPeak Wealth LLC increased its stake in Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock valued at $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc lifted its stake in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock valued at $8,317,000 after acquiring an additional 941 shares during the last quarter. Tri Locum Partners LP lifted its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after acquiring an additional 8,949 shares during the last quarter. Tidal Investments LLC lifted its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after acquiring an additional 711 shares during the last quarter. Finally, Catalytic Wealth RIA LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $1,334,000. 83.31% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
REGN has been the topic of several analyst reports. Oppenheimer lowered their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Citigroup began coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a "neutral" rating and a $895.00 target price for the company. Finally, StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $1,099.55.
Check Out Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals stock traded down $25.70 during midday trading on Friday, reaching $756.81. 1,374,476 shares of the stock traded hands, compared to its average volume of 530,457. The stock's fifty day moving average is $992.70 and its 200-day moving average is $1,033.92. Regeneron Pharmaceuticals, Inc. has a 12 month low of $753.69 and a 12 month high of $1,211.20. The stock has a market cap of $83.17 billion, a P/E ratio of 18.93, a PEG ratio of 3.04 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.48% of the company's stock.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
See Also
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
